目的 探討生脈注射液聯(lián)合烏司他丁治療感染性休克的臨床療效。方法 對(duì)2013年3月-2016年3月在屯昌縣人民醫(yī)院接受治療的感染性休克患者80例，隨機(jī)分為對(duì)照組（40例）和治療組（40例）。對(duì)照組患者靜脈滴注注射用烏司他丁，20萬U加入生理鹽水200 mL，2次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注生脈注射液，60 mL加入生理鹽水250 mL，1次/d。兩組患者均連續(xù)治療7 d。比較兩組患者治療前后臨床效果、血清細(xì)胞因子水平和免疫功能變化。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為80.00%和95.00%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、血小板（PCT）、內(nèi)皮素-1（ET-1）及NO水平都顯著降低，IL-10則升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)水平優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者CD³⁺和CD⁴⁺水平及CD⁴⁺/CD⁸⁺都顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者免疫功能顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 生脈注射液聯(lián)合烏司他丁治療感染性休克療效顯著，可增強(qiáng)機(jī)體免疫功能及減輕炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study Shengmai Injection combined with ulinastatin in treatment of septic shock. Methods Patients (80 cases) with septic shock in Tunchang County People's Hospital from March 2013 to March 2016 were randomly divided into control (40 cases) and treatment (40 cases) groups. Patients in the control group were iv administered with Ulinastatin for injection, 0.2 million U added into normal saline 200 mL, twice daily. Patients in the treatment group were iv administered with Shengmai Injection on the basis of the control group, 60 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy, serum inflammatory factors level, and immune function in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, IL-6, TNF-α, PCT, ET-1, and NO levels in two groups were significantly decreased, IL-10 was obviously increased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in two groups were significantly increased, and there was difference in the groups (P<0.05). And immune function of patients in the treatment group was significantly better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Shengmai Injection combined with ulinastatin has a significant effect in treatment of septic shock, can enhance immune function and reduce inflammation, which has a certain clinical application value.